Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson’s disease

Parkinson’s disease (PD) is associated with increased iron levels in the substantia nigra (SNc). This study evaluated whether the iron chelator, deferiprone, is well tolerated, able to chelate iron from various brain regions and improve PD symptomology. In a randomised double-blind, placebo controll...

Descripción completa

Detalles Bibliográficos
Autores principales: Martin-Bastida, Antonio, Ward, Roberta J., Newbould, Rexford, Piccini, Paola, Sharp, David, Kabba, Christina, Patel, Maneesh C., Spino, Michael, Connelly, John, Tricta, Fernando, Crichton, Robert R., Dexter, David T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5431100/
https://www.ncbi.nlm.nih.gov/pubmed/28469157
http://dx.doi.org/10.1038/s41598-017-01402-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5431100/
https://www.ncbi.nlm.nih.gov/pubmed/28469157
http://dx.doi.org/10.1038/s41598-017-01402-2

Ejemplares similares